Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands
- PMID: 16395110
- DOI: 10.1097/01.inf.0000195594.41449.c6
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands
Abstract
Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy.
Similar articles
-
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.BMC Infect Dis. 2012 Feb 8;12:35. doi: 10.1186/1471-2334-12-35. BMC Infect Dis. 2012. PMID: 22316426 Free PMC article.
-
Challenges for development of meningococcal vaccines in infants and children.Expert Rev Vaccines. 2011 Mar;10(3):335-43. doi: 10.1586/erv.11.3. Expert Rev Vaccines. 2011. PMID: 21434801 Review.
-
[Impact of systematic vaccination with the antimeningococcal C conjugated vaccine in a health area in Andalusia].Rev Esp Salud Publica. 2005 Nov-Dec;79(6):655-63. doi: 10.1590/s1135-57272005000600005. Rev Esp Salud Publica. 2005. PMID: 16457057 Spanish.
-
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.Arch Dis Child. 2007 Oct;92(10):909-15. doi: 10.1136/adc.2006.111500. Arch Dis Child. 2007. PMID: 17895339 Free PMC article. Review.
-
Meningococcal disease: the advances and challenges of meningococcal disease prevention.Hum Vaccin. 2011 Aug;7(8):828-37. doi: 10.4161/hv.7.8.16270. Epub 2011 Aug 1. Hum Vaccin. 2011. PMID: 21832882 Review.
Cited by
-
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.Expert Rev Vaccines. 2009 Jul;8(7):851-61. doi: 10.1586/erv.09.48. Expert Rev Vaccines. 2009. PMID: 19538112 Free PMC article. Review.
-
Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?Clin Vaccine Immunol. 2009 Oct;16(10):1521-3. doi: 10.1128/CVI.00274-09. Epub 2009 Aug 19. Clin Vaccine Immunol. 2009. PMID: 19692627 Free PMC article.
-
Vaccination strategies for the prevention of meningococcal disease.Hum Vaccin Immunother. 2018 May 4;14(5):1203-1215. doi: 10.1080/21645515.2018.1451287. Epub 2018 Apr 13. Hum Vaccin Immunother. 2018. PMID: 29543535 Free PMC article. Review.
-
Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.Pathog Glob Health. 2022 Mar;116(2):85-98. doi: 10.1080/20477724.2021.1972663. Epub 2021 Sep 27. Pathog Glob Health. 2022. PMID: 34569453 Free PMC article. Review.
-
Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.BMC Med Res Methodol. 2019 Jan 5;19(1):1. doi: 10.1186/s12874-018-0650-3. BMC Med Res Methodol. 2019. PMID: 30611213 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical